EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Micromem Technologies Inc.: Exhibit 99.1 - Filed by newsfilecorp.com

Exhibit 99.1

Condensed Interim Consolidated Financial Statements of

MICROMEM TECHNOLOGIES INC.

For the Three and Nine Months Ended July 31, 2013 and 2012

(Unaudited – expressed in U.S.dollars)



MICROMEM TECHNOLOGIES INC.
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
TABLE OF CONTENTS

Section Page
A)   Condensed Interim Consolidated Financial Statements (unaudited)  3-6
B)   Footnotes:  
1.   Reporting Entity and Nature of Business 7
2.   Going Concern 8
3.   Basis of Presentation 9
4.   Summary of Significant Accounting Policies  10
5.   New Standards and Interpretations Issued but not yet Adopted  10
6.   Promissory Note Receivable  11
7.   Deferred Development Costs  12
8.   Intangible Assets and Patents  12
9.   Share Capital, Stock Options and Loss per Share  13-14
10.   Private Placements, Derivative Warrant Liability and Common Share Purchase Warrants 15-16
11.   Bridge Loans  16-17
12.   Contributed Surplus  18
13.   Income Taxes  19
14.   Expenses  20
15.   Management Compensation and Related Party Transactions  21
16.   Commitments  22
17.   Contingencies  22
18.   Financial Risk Management  23-25
19.   Segmented Information  25
20.   Subsequent Events  25-26

2



MICROMEM TECHNOLOGIES INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(Unaudited, expressed in United States dollars)

 

  July 31,     October 31,  

 

  2013     2012  

 

        (audited)  

Assets

           

Current assets:

           

   Cash

$  84,817   $  245,029  

   Deposits and other receivables

  162,184     46,062  

   Promissory note receivable (Note 6)

  -     -  

 

  247,001     291,091  

 

           

Property and equipment, net

  11,438     5,787  

Deferred development costs (Note 7)

  994,270     718,163  

Intangible assets, net (Note 8)

  101,599     116,113  

Patents, net (Note 8)

  144,448     49,124  

 

$  1,498,756   $  1,180,278  

 

           

Liabilities and Shareholders' Equity (Deficiency)

           

Current liabilities:

           

   Bridge loans (Note 11)

$  290,014   $  442,934  

   Accounts payable and accrued liabilities

  487,027     579,830  

   Derivative warrant liability (Note 10)

  488,551     1,061,544  

 

$  1,265,592   $  2,084,308  

Shareholders' Equity (Deficiency)

           

   Share capital: (Note 9)

           

      Authorized:

           

         2,000,000 special preference shares, redeemable, voting

           

         Unlimited common shares without par value

           

      Issued and outstanding:

           

         151,150,225 common shares (2012: 136,430,555)

$  56,611,848   $  54,728,239  

   Equity component of bridge loans (Note 11)

  1,557     1,557  

   Contributed surplus (Note 12)

  27,014,965     26,634,177  

   Deficit

  (83,395,206 )   (82,268,003 )

 

  233,164     (904,030 )

 

           

 

$  1,498,756   $  1,180,278  

"Joseph Fuda" (Signed)                       
Joseph Fuda, Director

"David Sharpless" (Signed)                 
David Sharpless, Director

See accompanying notes.

3



MICROMEM TECHNOLOGIES INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
(Unaudited, expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012

 

  Three Months Ended July 31     Nine Months Ended July 31  

 

  2013     2012     2013     2012  

 

                       

Costs and expenses (income):

                       

   Administration (Note 14)

$  73,699   $  181,497   $  297,164   $  399,970  

   Professional, other fees and salaries (Note 14)

  333,430     352,894     1,056,532     1,065,743  

   Stock based compensation (Note 9)

  -     -     168,386     430,856  

   Research and development

  19,406     724     122,738     12,201  

   Travel and entertainment

  49,397     39,954     138,881     107,671  

   Amortization of property and equipment

  1,132     1,103     3,205     3,309  

   Amortization of intangible assets and patents (Note 8)

  4,838     4,838     14,514     14,514  

   Foreign exchange

  3,235     1,805     3,653     (2,970 )

Loss from operations

  485,137     582,815     1,805,073     2,031,294  

 

                       

Other expenses

                       

   (Gain) loss on revaluation of embedded derivatives

  -     -     (40,750 )   -  

   (Gain) loss on revaluations of derivative warrants liability

  (224,106 )   (75,736 )   (1,070,202 )   1,349,945  

 

                       

Net loss before income taxes

  (261,031 )   (507,079 )   (694,121 )   (3,381,239 )

 

                       

   Income taxes (Note 13)

  -     -     -     -  

 

                       

Net loss and comprehensive loss

$  (261,031 ) $  (507,079 ) $  (694,121 ) $  (3,381,239 )

 

                       

Loss per share - basic and diluted

  -     -     -   $  (0.03 )

 

                       

Weighted average number of shares

  149,217,974     125,684,658     144,440,667     120,988,786  

See accompanying notes.

4



MICROMEM TECHNOLOGIES INC.
CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited, expressed in United States dollars)
 
For the three and Nine months ended July 31, 2013 and 2012

 

  Three Months Ended July 31     Nine Months Ended July 31  

 

  2013     2012     2013     2012  

 

                       

Cash flows from operating activities:

                       

   Net loss

$  (261,031 ) $  (507,079 ) $  (694,121 ) $   (3,381,239 )

   Adjustments to reconcile loss for the period to net cash used in operating activities:

               

      Amortization of patents and intangible assets

  4,838     4,838     14,514     14,514  

      Amortization of property and equipment

  1,132     1,103     3,205     3,309  

      Accretion expense

  -     687     19,381     3,177  

      Stock based compensation

  -     -     168,386     430,856  

      (Decrease) Increase in deposits and other receivables

  (35,234 )   (22,222 )   (116,122 )   (89,680 )

      Decrease in accounts payable and accrued liabilities

  66,402     (131,698 )   (92,840 )   (544,891 )

      Gain (loss) on revaluation of derivative warrant liability

  (224,106 )   (75,736 )   (1,070,202 )   1,349,945  

      (Gain) loss on revaluation of embedded derivatives

  -     -     (40,750 )   -  

Net cash used in operating activities

  (447,999 )   (730,107 )   (1,808,549 )   (2,214,009 )

 

                       

Cash flows from investing activities:

                       

   Purchase of property and equipment

  1,678     -     (8,817 )   -  

   Patents

  (85,205 )   18,004     (112,936 )   18,004  

   Deferred development costs

  (57,235 )   (36,365 )   (258,495 )   81,554  

Net cash used in investing activities

  (140,762 )   (18,361 )   (380,248 )   99,558  

 

                       

Cash flows from financing activities:

                       

   Issue of common shares

  453,046     828,762     2,139,971     1,674,049  

   Subscription received

  -     -     20,167     -  

   Bridge loans advances

  17,071     -     61,606     634,366  

   Bridge loan repayments

  (17,071 )   (93,001 )   (193,159 )   (222,545 )

Net cash provided by financing activities

  453,046     735,761     2,028,585     2,085,870  

 

                       

Increase (decrease) in cash

  (135,715 )   (12,707 )   (160,212 )   (28,581 )

 

                       

Cash, beginning of period

  220,532     28,188     245,029     44,062  

 

                       

Cash, end of period

$  84,817   $  15,481   $  84,817     15,481  

 

                       

Supplemental cash flow information:

                       

   Interest paid (Classified in operating activities)

  17,071     17,071     66,422     46,008  

   Income taxes paid

  -           -        

See accompanying notes.

5



MICROMEM TECHNOLOGIES INC.
Condensed Interim Consolidated Statements of Changes in Shareholders' Equity
(Unaudited, expressed in United States dollars)

 

  Number of     Share capital     Contributed     Equity component     Deficit     Total  

 

  Shares           surplus     0f Bridge loan              

 

        (Note 9 )   (Note 12 )                  

Balance as at November 01, 2011

  116,149,718   $  51,774,555   $  25,986,276   $  -   $ (79,170,059 ) $  (1,409,228 )

 

                                   

Private placement of units for cash

  6,344,899     1,040,899     -     -     -     1,040,899  

Financing costs

  -     (16,457 )         -     -     (16,457 )

Stock based compensation

  -     -     430,856     -     -     430,856  

Warrants issued on private placements

  -     (356,364 )   66,997     -     -     (289,367 )

Warrants extended

  -     -     358,983     -     (1,322,879 )   (963,896 )

Warrants exercised

  12,075,858     1,499,713     -     -     -     1,499,713  

Fair value of warrants exercised

  -     558,993     (208,935 )   -     -     350,058  

Equity portion of bridge loan

  -     -     -     1,557     -     1,557  

Shares issued on conversion of bridge loan

  1,860,080     226,900     -     -     -     226,900  

Net loss and comprehensive loss

  -     -     -     -     (1,775,065 )   (1,775,065 )

Balance at October 31, 2012

  136,430,555     54,728,239     26,634,177     1,557     (82,268,003 )   (904,030 )

 

                                   

Balance at November 01, 2012

  136,430,555     54,728,239     26,634,177     1,557     (82,268,003 )   (904,030 )

 

                                -  

Private placement of units for cash

  9,452,424     1,505,686     -     -     -     1,505,686  

Financing costs

  -     (35,482 )   -     -     -     (35,482 )

Stock based compensation

  -     -     168,386     -     -     168,386  

Warrants issued on private placement

  -     (464,855 )   153,081     -     -     (311,774 )

Warrants extended

  -     -     106,996     -     (433,082 )   (326,086 )

Warrants exercised

  5,267,246     689,934     -     -     -     689,934  

Fair value of warrants exercised

  -     188,326     (47,675 )   -     -     140,651  

Net loss and comprehensive loss

  -     -     -     -     (694,121 )   (694,121 )

Balance at July 31, 2013

  151,150,225   $  56,611,848   $  27,014,965   $  1,557   $ (83,395,206 ) $  233,164  

6



MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 

1.

REPORTING ENTITY AND NATURE OF BUSINESS

   

Micromem Technologies Inc. (“Micromem” or the “Company”) is a corporation incorporated under the laws of the Province of Ontario, Canada. The principal business address of the Company is 121 Richmond Street West, Suite 304, Toronto, Ontario, Canada.

   

The Company currently operates as a developer of magnetic sensor technology and applications of this technology. The Company has not generated revenue through July 31, 2013 and is devoting substantially all of its efforts to the development of its technologies.

   

These unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries:


  (i)

Micromem Applied Sensors Technology, Inc. (“MAST”) incorporated in November 2007 and domiciled in Delaware, United States. MAST has the primary responsibility for the further development of the Company’s technologies in conjunction with various strategic development partners.

     
  (ii)

7070179 Canada Inc., incorporated in October 2008 under the Canada Business Corporations Act in Ontario, Canada. The Company has assigned to this entity its rights, title and interests in certain patents which it previously held, directly in exchange for common shares of this entity.

     
  (iii)

Memtech International Inc., Bahamas; Memtech International (USA) Inc., Delaware, United States; Pageant Technologies (USA) Inc., United States; Pageant Technologies Inc., Barbados; and Micromem Holdings (Barbados) Inc., Barbados. All of these entities are inactive.

These unaudited interim condensed consolidated financial statements were authorized for issuance and release by the Company’s Board of Directors on September 27, 2013.

7


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
2.

GOING CONCERN

   

These unaudited interim condensed consolidated financial statements have been prepared on the “going concern” basis in accordance with International Financial Reporting Standards (“IFRS”), which presumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business for the foreseeable future.

   

There are uncertainties that cast doubt about the Company’s ability to continue as a going concern for a reasonable period of time in future. During the nine months ending July 31, 2013, the Company reported a net loss and comprehensive loss of $694,121 (2012: $3,381,239) a working capital deficiency (current assets less current liabilities excluding derivative warrant liability) of $530,040 (2012: $731,673) and negative cash flow from operations of $1,808,549 (2012: $2,214,009).

   

The Company continues to focus its development efforts on existing projects in order to develop commercial applications for these projects. It will be necessary for the Company to raise additional funds for the continued development, testing and commercial exploitation of its technologies. To date, the Company has raised financing through successive unit private placements, through the exercise of common share stock options and through the exercise of common share purchase warrants. It has also secured periodic bridge loans.

   

If the “going concern” assumption were not appropriate for these unaudited interim condensed consolidated financial statements, then adjustments would be necessary to the carrying value of assets and liabilities, the reported expenses and the classifications used for the statement of financial position. In this case, such adjustments could be material.

8


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
3.

BASIS OF PRESENTATION


  a)

Statement of compliance:

     
 

These unaudited interim condensed consolidated interim financial statements have been prepared in accordance with IAS 34, Interim Financial Reporting.

     
  b)

Basis of measurement:

     
 

These unaudited interim condensed consolidated financial statements have been prepared on the historical cost basis, except for financial instruments designated at fair value through profit and loss, which are stated at their fair value.

     
  c)

Functional and presentation currency:

     
 

These unaudited interim condensed consolidated financial statements are presented in United States dollars (“U.S. dollars”), which is also the Company’s functional currency.

     
  d)

Use of estimates and judgments:

     
 

The preparation of the unaudited interim condensed consolidated financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

     
 

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Refer to the audited consolidated financial statements for the year ended October 31, 2012 for estimates and judgments which remain unchanged as at July 31, 2013.

9


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
4.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

   

These unaudited interim condensed consolidated financial statements follow the same accounting policies and methods of application as set out in the audited consolidated financial statements for the year ended October 31, 2012. These statements should be read in conjunction with the audited consolidated financial statements for the year ended October 31, 2012.

   
5.

NEW STANDARDS AND INTERPRETATIONS ISSUED BUT NOT YET ADOPTED

   

Certain new standards, interpretations, amendments and improvements to existing standards were issued by the IASB or International Financial Reporting Interpretations Committee (“IFRIC”) that are mandatory for future accounting periods. The standards which are impacted that are applicable to the Company include:


  (a)

IFRS 9 – financial assets

     
  (b)

IFRS 10 – condensed financial statements

     
  (c)

IFRS 11 – joint arrangements

     
  (d)

IFRS 12 – disclosure of interests in other entities

     
  (e)

IFRS 13 – fair value measurement

IFRS 9 proposed amendments are effective for annual reporting periods commencing on January 1, 2015; the proposed amendments for IFRS 10-13 are effective for annual reporting periods commencing on January 1, 2013.

The Company is currently assessing the impact of these proposed amendments.

10


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
6.

PROMISSORY NOTE RECEIVABLE

   

In April 2009, the Company advanced $200,000 to a private company incorporated in New Jersey that was, at that time, a strategic development partner of the Company. The Company and the private company executed a promissory note with respect to the $200,000 advance stipulating the following terms and conditions:


  a)

Maturity date of September 30, 2010.

     
  b)

Interest payable on a quarterly basis in arrears calculated from August 1, 2009 at a rate of 10%. In July 2011, the interest rate on the promissory note increased to 18%.

     
  c)

Secured by a first priority security interest over all of the assets of the private company.

At October 31, 2012 the balance outstanding was $101,853 and this amount has been fully reserved. The Company served notice to the private company that it was demanding payments under the terms of the promissory note and the security agreement and has received judgment in its favor during the year ended October 31, 2012. The Company continues to pursue collection of this fully reserved note. The outstanding balance of principal and interest at July 31, 2013 is $116,479 which is fully reserved.

11


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
7.

DEFERRED DEVELOPMENT COSTS

   

The breakdown of development costs that have been capitalized is as follows (Note 20):


  At November 1, 2011 $  646,606  
  Additions   71,557  
  Year ended October 31, 2012 $  718,163  
         
  At November 1, 2012 $  718,163  
  Additions   276,107  
  Nine months ended July 31 2013 $  994,270  

8.

INTANGIBLE ASSETS AND PATENTS

   

Intangible assets comprise the costs which the Company has capitalized relating to the technical expertise and know-how that the Company has developed with respect to the commercialization efforts relating to its sensor technology. There were no additions to intangible assets during the period ending July 31, 2013 (2012-nil).

   

The Company reported additions of $112,936 to patents during the period ended July 31, 2013 (2012-$nil).

12


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
9.

SHARE CAPITAL, STOCK OPTIONS AND LOSS PER SHARE


  a)

Share Capital

     
 

Authorized and outstanding:

     
 

The Company has two classes of shares as follows:


  i)

Special redeemable voting preference shares, 2,000,000 authorized, none are issued and outstanding.

     
  ii)

Common shares without par value – an unlimited number authorized.


      Number of     Amount  
      Shares   $  
               
  Balance at October 31, 2011   116,149,718   $  51,774,555  
               
  Private placement of units for cash (Note 15)   6,344,899     1,040,899  
  Warrants exercised   12,075,858     1,499,713  
  Warrants issued on private placements (Note 15)   -     (356,364 )
  Fair value of warrants exercised   -     558,993  
  Share issued on conversion of bridge loans (Note 16)   1,860,080     226,900  
  Financing costs   -     (16,457 )
  Balance at October 31, 2012   136,430,555   $  54,728,239  
               
  Private placement of units for cash (Note 15)   9,452,424     1,505,686  
  Warrants exercised   5,267,246     689,935  
  Warrants issued on private placements (Note 15)   -     (464,855 )
  Fair value of warrants exercised   -     188,326  
  Financing costs         (35,483 )
  Balance at July 31, 2013   151,150,225   $  56,611,848  

13


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
9.

SHARE CAPITAL, STOCK OPTIONS AND LOSS PER SHARE (Cont’)


  b)

Stock Options

     
 

A summary of the status of the Company’s fixed stock option plan through July 31, 2013 and changes during the periods is as follows:


      Options     Weighted average  
      (000 )   exercise price  
  Outstanding, November 01   11,175     0.47  
  Granted   2,000     0.35  
  Expired   (540 )   (0.44 )
  Forfeited   (2,720 )   (1.20 )
  Outstanding, October 31,   9,915     0.24  
  Granted   1,090     0.30  
  Expired   (610 )   0.40  
  Outstanding, July 31, 2013   10,395     0.24  

During the nine month ended July 30, 2013 the Company issued a total of 1,090,000 (2012 – 2,000,000) stock options to officers, directors and employees. The Company has the following stock options outstanding at July 31, 2013 (Note 20):

  Date of issue # Issued Strike Price Expiry Date
         
  April 5, 2011 125,000 0.35 April 5, 2016
  October 31, 2011 7,275,000 0.20 October 31, 2016
  April 10, 2012 1,905,000 0.35 April 10, 2017
  January 22, 2013 1,090,000 0.30 January 22, 2018
    10,395,000    

For the nine months ended July 31, 2013 the Company recorded a total expense of $168,386 (2012: $430,856) with respect to the issuance of these options, calculated in accordance with the Black Scholes option-pricing model.

14


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
10.

PRIVATE PLACEMENTS, DERIVATIVE WARRANT LIABILITY AND COMMON SHARE PURCHASE WARRANTS


  a)

Private Placements

     
 

In the nine months ended July 31, 2013 the Company reported total private placement financings pursuant to prospectus and registration exemptions set forth in applicable securities law as below:


      Nine months ending  
      July 31,2013     July 31,2012  
               
  Common shares issued   9,452,424     11,794,992  
  Warrants issued   9,452,424     11,794,992  
  Proceeds realized $  1,505,686   $  1,690,506  

 

In the nine months ended July 31, 2013 the Company realized proceeds of $689,934 from the exercise of 5,267,246 common share purchase warrants. (2012 - $1,499,713 proceeds from exercise of 12,075,858 common share purchase warrants).

   

  b)

Derivative Warrant Liability

   

 

The following summarizes the change in the balance reported as derivative warrant liability for the nine months ended July 31, 2013:


      July 31,     October 31,  
      2013     2012  
  Balance, beginning of period $  1,061,544   $  1,178,691  
  Fair value assigned in warrants in units issuances   311,774     289,367  
  Fair value assigned in warrants extended   326,086     963,896  
  Fair value assigned to warrants issued on settlements of debt   -     306,061  
  Fair value transferred to share capital for warrants exercised   (140,651 )   (348,948 )
  (Gain) loss on revaluation of warrants   (1,070,202 )   (1,327,523 )
    $  488,551   $  1,061,544  

15


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
10.

PRIVATE PLACEMENTS, DERIVATIVE WARRANT LIABILITY AND COMMON SHARE PURCHASE WARRANTS (Cont’d)


  c)

Share Purchase Warrants

     
  A summary of the outstanding common share purchase warrants and the changes during the period is as follows (Note 20):

            Weighted        
            average     Proceeds  
      Warrants     exercise price     Realized  
                     
  Balance outstanding at October 31,2011   26,672,637   $  0.23     -  
  Exercised   (12,075,858 )   (0.12 )   1,499,713  
  Expired   (3,108,792 )   (0.15 )   -  
  Granted   8,204,981     0.19     -  
  Balance outstanding at October 31, 2012   19,692,968   $  0.23     -  
  Exercised   (5,267,246 )   (0.13 )   689,934  
  Expired   (85,000 )   (0.15 )   -  
  Granted   9,452,424     0.21     -  
  Balance at July 31, 2013   23,793,146   $  0.27     -  

11.

BRIDGE LOANS


  (a)

On December 2, 2011, the Company secured $285,000 CDN of bridge loans from a group of arm’s length investors with maturities of six months. The loans are unsecured, bear interest at a rate of 2% per month (effective interest rate – 26%) and are convertible at the holder’s option at $0.12 USD per unit. Each unit upon conversion includes one common share and one common share purchase warrant with a one year expiry and an exercise price of $0.12 USD. The term of the loan was extended on a month to month basis in July 2012.

16


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
11.

BRIDGE LOANS (Cont’d)


  (b)

On September 4, 2012, the Company secured $125,000 CDN of bridge loans from a group of arm’s length investors with maturities of six months. The loans are unsecured, bear interest at a rate of 2% per month (effective interest rate – 26%) and are convertible at the holders’ option at $0.18 CDN per share. Each unit, upon conversion, includes one common share and one common share purchase warrant with a one year expiry and an exercise price of $0.22 CDN. This bridge loan was repaid during the quarter ending April 30, 2013.

The outstanding bridge loans at October 31, 2012 are summarized as follows:

      Loan     Loan     Total  
                     
  Principal   284,514     81,194     365,708  
  Embedded derivative   -     44,850     44,850  
  Interest Accrued   62,403     4,816     67,219  
  Interest Paid   (56,903 )   -     (56,903 )
  Accretion Expense   1,557     26,161     27,718  
  Gain on revaluation of embedded derivative   -     (4,101 )   (4,101 )
  Equity Portion of Bridge Loan - Conversion Feature   (1,557 )   -     (1,557 )
  Carrying value at October 31, 2012   290,014     152,920     442,934  

The outstanding bridge loans at July 31, 2013 are summarized as follows:

      Loan     Total  
               
  Principal   284,514     284,514  
  Interest Accrued   113,615     113,615  
  Interest Paid   (108,115 )   (108,115 )
  Accretion Expense   1,557     1,557  
  Equity Portion of Bridge Loan - Conversion Feature   (1,557 )   (1,557 )
  Carrying value at July 31, 2013   290,014     290,014  

17


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
12.

CONTRIBUTED SURPLUS


  Balance outstanding at November 1, 2011   25,986,276  
         
  Stock based compensation expense relating to stock options issued Note 9)   430,856  
  Common share purchase warrants      
         (a) Issued   66,997  
         (b) Extended   358,983  
  Fair value of warrants exercised   (208,935 )
  Balance at October 31, 2012   26,634,177  
         
  Stock based compensation expense relating to stock options issued (Note 9)   168,386  
  Common share purchase warrants      
         (a) Issued   153,081  
         (b) Extended   103,485  
  Fair value of warrants exercised   (44,164 )
  Balance at July 31, 2013   27,014,965  

18


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
13.

INCOME TAXES


  (a)

As of October 31, 2012 the Company has non-capital losses of approximately $20.0 million available to reduce future taxable income, the benefit of which has not been recognized in these consolidated financial statements. These tax losses expire as follows:


            Other        
      Canada     foreign     Total  
  2014 $  978,133   $  -   $  978,133  
  2015   3,212,751     -     3,212,751  
  2022   -     7,301     7,301  
  2023   -     9,667     9,667  
  2025   -     14,471     14,471  
  2026   2,403,497     5,254     2,408,751  
  2027   2,021,152     3,459     2,024,611  
  2028   10,483     55,519     66,002  
  2029   2,067,331     463,610     2,530,941  
  2030   2,794,877     1,471,700     4,266,577  
  2031   1,683,826     421,724     2,105,550  
  2032   1,991,469     382,177     2,373,646  
                     
    $  17,163,519   $  2,834,882   $  19,998,401  

In addition, the Company has available capital loss carry forwards of approximately $1.7 million to reduce future taxable capital gains, the benefit of which has not been recognized in these consolidated financial statements. These losses carry forward indefinitely.

19


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
14.

EXPENSES

   

Administration

   

The components of year to date general and administration expense is as follows ($000):


      2013     2012  
  General and administrative/other   48     35  
  Rent and occupancy cost   67     108  
  Interest expense   62     106  
  Accretion expense   19     -  
  Office insurance   46     65  
  Telephone   14     17  
  Investor relations, listing and filling fees   41     69  
      297     400  

Professional, other fees and salaries

The components of year to date professional, other fees and salaries expense is as follows ($000):

      2013     2012  
  Professional fees   180     159  
  Consulting fees   628     608  
  Salaries and benefits   249     300  
      1,057     1,067  

20


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
15.

MANAGEMENT COMPENSATION AND RELATED PARTY TRANSACTIONS


  (a)

Chairman:

     
 

In January 2011, the Board of Directors extended the Chairman’s contract on a month to month basis reflecting annual compensation amount of $150,000 CDN.

     
 

In the nine months ending July 31 2013 the Chairman was awarded a total of 75,000 options at a strike price of $0.30 per share (2012: 110,000 options at a strike price of $0.35 per share).

     
 

The total compensation paid to the Chairman during the period ended July 31 is summarized as follows:


            Stock Based  
            Compensation  
      Cash Compensation     Expense  
    $   $  
  2013   110,611     11,586  
  2012   111,660     23,694  

  (b)

Management and consulting fees:

     
 

Included in professional fees as reported are management and consulting fees paid or payable to individuals (or companies controlled by such individuals) who served as officers and directors of the Company. The total compensation paid to such parties during the period ended July 31, 2013 is as follows:


            Stock Based  
            Compensation  
      Cash Compensation     Expense  
    $   $  
  2013   408,370     23,172  
  2012   434,078     159,396  

21


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
16.

COMMITMENTS


  (a)

License Agreement:

     
 

Reference should be made to the License Agreement disclosures in the audited consolidated financial statements as of October 31, 2012. The license was executed in 2005 between the Company and the University of Toronto and the Ontario Centres of Excellence. The Company is committed to royalties of up to $1 million based on future revenues that it may receive relating to certain technology that was developed by the Company in conjunction with the University of Toronto. To date, the Company reports nil revenues and no liability under the license agreement.

     
  (b)

Operating Leases:

     
 

The Company secured new leased premises in June 2012. The lease term is for 5 years and stipulates base monthly rental expenses of $3,800 CDN. Lease commitments for these premises are as follows ($US):


  Less than 1 year $  44,000  
  2-5 years   136,000  
  More than 5 years   -  
    $  180,000  

17.

CONTINGENCIES

   

The Company has agreed to indemnify its directors and officers and certain of its employees in accordance with the Company’s by-laws. The Company maintains insurance policies that may provide coverage against certain claims.

22


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
18.

FINANCIAL RISK MANAGEMENT

   

The Company is exposed to a variety of financial risks by virtue of its activities: market risk (including foreign exchange risk and interest rate risk) liquidity risk and credit risk. The overall risk management program focuses on the unpredictability of financial markets and seeks to minimize potential adverse effects on financial performance. Risk management is carried out under policies approved by the Board of Directors. Management is charged with the responsibility of establishing controls and procedures to ensure that financial risks are mitigated in accordance with the approved policies.


  (a)

Market Risk:


  i.

Foreign exchange risk:

     
 

The Company currently incurs expenses in Canadian dollars. The total monetary financial instruments are in a net liabilities position. Management monitors the Canadian net liability position on a periodic basis throughout the course of the year and adjusts the total net monetary liability balance accordingly.

     
 

The condensed consolidated financial statements include balances that are denominated in Canadian dollars as follows:


      2013     2012  
               
  Cash and cash equivalents $  56,229   $  9,458  
  Deposits and other receivables   166,596     122,367  
  Accounts payable and accrued liabilities   219,785     (409,936 )
  Bridge loan   -     (257,960 )

23


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
18.

FINANCIAL RISK MANAGEMENT (Cont’d)


  (b)

Market Risk: (Cont’d)


 

A 10% strengthening of the US dollar against the Canadian dollar would have increased the net equity by approximately $3,000 (2012 – approximately $71,000) due to a reduction in the value of net liability balance. A 10% weakening of the US dollar against the Canadian dollar would have had the equal but opposite effect.

     
  ii.

Interest rate risk:

     
 

Cash flow interest rate risk is the risk that the future cash flow of a financial instrument will fluctuate because of changes in market interest rates.

     
 

Financial assets and financial liabilities with variable interest rates expose the Company to cash flow interest rate risk. The Company’s cash and promissory note receivable earn interest at market rates. The Company manages its interest rate risk by maximizing the interest income earned on excess funds while maintaining the liquidity necessary to conduct operations on a day-to-day basis. Fluctuations in market rates of interest may have an impact on the Company’s results of operations.


  (c)

Liquidity risk:

     
 

Liquidity risk is the risk that the Company will not be able to meet its obligations as they fall due.

     
 

The Company manages its liquidity risk by forecasting cash flows from operations and anticipated investing and financing activities. Senior management is actively involved in the review and approval of planned expenditures.

     
 

All financial liabilities are due within 1 year from the balance sheet at July 31, 2013.

24


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
18.

FINANCIAL RISK MANAGEMENT (Cont’d)


  (d)

Credit risk:

     
 

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company’s cash and cash equivalents, deposit and other receivables. The carrying amount of financial assets represents maximum credit exposure.

     
 

As at July 31, 2013, the Company reports a working capital deficiency of $530,040 (measured as current assets less current liabilities excluding the derivative warrant liability) and has certain financial commitments (Notes 15 and 16), the majority of which are due within one year. It must continue to raise financing in order to meet its current obligations.


19.

SEGMENTED INFORMATION

   

There is one operating segment of the business being the development and commercialization efforts with respect to the Company's proprietary memory and sensor applications. Currently, the predominant market segment that the Company is pursuing is the North American market for such technology.

   
20.

SUBSEQUENT EVENTS

   

The Company reports the following subsequent events:


  a)

It issued 1,792,935 common shares via unit private placements and received proceeds of $289,869 CDN (approximately $280,000 US). Each unit consisted of one common share at a price of $0.16 per share and one common share purchase warrant at a price of $0.21 per warrant. The common share purchase warrants issued expire in 12 months from the date of issuance.

     
  b)

The Company reported on August 12th that it received a $4 million contract from a US based oil company to develop a proof of concept prototype. The contract specifies multiple phases and development milestones over the next 8-12 months. Subsequently the Company reported that the full value of the contract, with successful completion of all milestones, could approximate $25 million.

25


MICROMEM TECHNOLOGIES INC.
 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Expressed in United States dollars)
 
For the three and nine months ended July 31, 2013 and 2012
 
   
20.

SUBSEQUENT EVENTS (Cont’d)


  c)

The Company announced on August 19th on the progress of a potential licensing agreement with a US based automotive company. The Company has completed a proof of concept prototype and is now pursuing discussions with industrial manufacturing companies for potential large scale production quantities.

     
  d)

The Company extended the expiry date for a period of 12 months with respect to a total of 728,572 common share purchase warrants originally issued in 2012 and repriced these warrants from the original price of $0.17 per warrant to $0.21 per warrant.

     
  e)

The Company issued a total of 780,000 common stock options to officers, directors and employees. The stock options have a 5 year term through August 2018 at a strike price of $0.27 CDN per share.

**************************************

26